Tuesday, March 28, 2017


Glendale, California (PRWEB) March 06, 2017


EAST HANOVER, N.J., March 6, 2017 /PRNewswire/ -- Novartis announced today a new analysis (post hoc) of an uncontrolled extension study which shows moderate to severe plaque psoriasis patients treated with Cosentyx® (secukinumab) rapidly regained clear or almost clear skin (Psoriasis Area Severity Index, PASI 100 o.....   [READ MORE]

About The Health Technology - Contact Us - Advertise With Us - Privacy Guidelines